Sourav Ghorai
Enanta Pharmaceuticals (United States), Calibr at Scripps Research, University of Illinois at Chicago, University of Illinois Chicago Graduate College, University of Calcutta
0000-0001-8093-5655
About
Dr. Sourav Ghorai is a Scientist in the Medicinal Chemistry department at Enanta Pharmaceuticals, Massachusetts, USA. He obtained his BSc degree in Chemistry from University of Calcutta in 2012, followed by MSc degree in Chemistry from Indian Institute of Technology, Kanpur, India in 2014. Then, he joined the University of Illinois at Chicago to work with Prof. Daesung Lee, where he obtained MS degree in Chemistry in 2018 and doctorate degree in synthetic organic chemistry in 2020. Then, he joined Calibr at Scripps Research to work with Dr. Arnab Chatterjee as postdoctoral associate in 2020-2021.
He has served as ad hoc reviewer for multiple journals in both medicinal chemistry and synthetic organic chemistry fields. He is a Review Editor on the Editorial Board of Frontiers in Chemistry (Medicinal and Pharmaceutical Chemistry section).
Dr. Sourav Ghorai is an experienced medicinal chemist (research interests: structure-based drug design, SAR studies, lead optimization, preclinical development, PROTAC synthesis, process development, patent writing) as well as a synthetic organic chemist (research interests: method development, silver catalysis, total synthesis, HDDA reaction). His current research focus is to design and synthesize small molecules, peptides/peptidomimetics for the treatment of liver and viral diseases (SARS-Cov2, NASH, HBV).
Employment
-
Enanta Pharmaceuticals (United States) Senior Scientist2024 - Present
-
Enanta Pharmaceuticals (United States) Scientist2021 - 2023
-
Calibr at Scripps Research Postdoctoral Associate2020 - 2021
Education
-
University of Illinois at Chicago PhD2014 - 2020
-
University of Illinois Chicago Graduate College MS2014 - 2018
-
University of Calcutta BSc2009 - 2012
Projects & Funding
Projects & funding information is unavailable.
Publications (24)
- Orally Bioavailable SARS-CoV-2 Protease Inhibitors Bearing a Hydroxymethyl Ketone Warhead Save
- Prediction of SafD adhesin strong binding peptides for pilus proteins assembly suppression in the prevention of Salmonella-induced biofilm formation using virtual mutagenesis studies Save
- Prediction of SafD adhesin strong binding peptides for pilus proteins assembly suppression in the prevention of Salmonella-induced biofilm formation using virtual mutagenesis studies Save
- Fused Heterotetracyclic Antiviral Agents Save
- Fused heterocyclic antiviral agents Save
- Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead Save
- Pyrimidinone-Containing 17-beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors Save
- Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Covalent Warhead Save
- 17-Beta-hydroxysteroid Dehydrogenase type 13 inhibitors and methods of use thereof Save
- CHARACTERIZATION OF MOUSE AND HUMAN HSD17B13 STRUCTURE AND ACTIVITY Save